BMY 42239
Latest Information Update: 27 Jul 1994
At a glance
- Originator Bristol-Myers Squibb
- Class Anticoagulants; Antiplatelets
- Mechanism of Action Epoprostenol agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis